Correlation between serum levels of heparin binding protein, pentraxin-3 and chronic obstructive pulmonary disease complicated with pulmonary infection

doi:10.3877/cma.j.issn.1674-1358.2020.03.009

Abstract

Abstract:

Objective

To investigate the correlation between the levels of serum heparin binding protein (HBP), pentraxin-3 (PTX3) and chronic obstructive pulmonary disease (COPD) with pneumonia.

Method

From March 2016 to March 2018, a total of 60 COPD patients (COPD group), 45 COPD patients with pneumonia (COPD with pneumonia group) and 35 healthy people (control group) were selected in Respiratory Department of Xiangyang Central Hospital. The levels of serum HBP and PTX3 were measured by enzyme-linked immunosorbent assay, and the correlation between levels of HBP, PTX3 and COPD was analyzed by Spearman correlation analysis.

Results

The differences in smoking history, complications, C-reactive protein (CRP), procalcitonin (PCT) and forced vital capacity rate of one second [FEV1/FVC(%)] among the three groups were significantly different (all P < 0.05). The FEV1/FVC(%) and FVC of COPD group and COPD with pneumonia group decreased significantly compared with control group; but the levels of interleukin (IL-8), tumor necrosis factor-α (TNF-α), CRP and PCT increased, with significant differences (all P < 0.05). Compared with COPD group, the levels of CRP [(68.9 ± 3.5) mg/L vs. (45.1 ± 1.67) mg/L] and PCT [(28.98 ± 5.9) μg/L vs. (18.34 ± 6.7) μg/L] decreased significantly (t = 4.102, P = 0.035). The levels of serum HBP and PTX3 in three groups were significanly different (F = 7.36, P = 0.003; F = 7.36, P = 0.003). Compared with COPD with pneumonia group [HBP: (558.3 ± 19.4) pg/ml, PTX3: (7.9 ± 0.5) ng/L], the levels of HBP [(372.0 ± 22.0) pg/ml] and PTX3 [(5.9 ± 0.3) ng/L] decreased significantly (t = 5.289, P = 0.21; t = 3.104, P = 0.039). Serum HBP and PTX3 were negatively correlated with FEV1 predictive value and FEV1/FVC(%), with significant differences (all P < 0.05); but were positively correlated with IL-8, TNF-α, CRP and PCT (all P < 0.05). The ROC curves were constructed taken COPD with pneumonia group as positive group and control group as negative group. The results showed that the sensitivity, specificity and positive predictive value of HBP and PTX3 were significantly higher than those of CRP, PCT, IL-8 and TNF-α (all P < 0.05).

Conclusions

The serum levels of HBP and PTX3 could be used to diagnose the COPD patients with pulmonary inflammation, with had important value in evaluating the condition and severity of COPD.

Key words: Chronic obstructive pulmonary disease, Pneumonia, Heparin binding protein, Pentraxin-3

Yuandong Huang, Jiafu He, Xiansheng Zeng, Xiangyang Li, Juanjuan Xu, Dandan Tang. Correlation between serum levels of heparin binding protein, pentraxin-3 and chronic obstructive pulmonary disease complicated with pulmonary infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(03): 229-234.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2020.03.009

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2020/V14/I03/229

Figures/Tables 5

References 21

[1]	Colarusso C, Terlizzi M, Molino A, et al. Role of the inflamma some in chronic obstructive pulmonary disease(COPD)[J]. Oncotarget, 2017,8(47):81813-81824.
[2]	Jacob S, Gunnar E, Magnus E, et al. Breathlessness and incidence of COPD, cardiac events and all-cause mortality: A 44-year follow-up from middle age throughout life[J]. PLoS One,2019,14(3):e0214083.
[3]	李寒春, 唐凤鸣, 罗麟洁, 等. 血清正五聚蛋白3在慢阻肺中的临床意义及与高敏C反应蛋白等的相关性研究[J]. 四川医学,2018,39(1): 21-24.
[4]	潘立萍, 苏冬菊, 鲍永霞, 等. IL-17, IL-10及HBP变化与AE-COPD感染程度关系的研究进展[J]. 东南大学学报:医学版,2017,36(2):298-301.
[5]	Thulborn SJ, Dilpazir M, Haldar K, et al. Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD[J]. Int J Chro Obstruct Pulmon Dis,2017,12(21):1199.
[6]	Cosentino ER, Landolfo M, Bentivenga C, et al. Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study[J]. BMC Cardiovasc Disord,2019,19(1):134-136.
[7]	Marcos PJ, Sanjuán P, Huerta A, et al. Relationship between severity classification of acute exacerbation of chronic obstructive pulmonary disease and clinical outcomes in hospitalized patients[J]. Cureus,2017,9(1):e988.
[8]	Abd-Elaziz AA, Alwahsh RA, Abd-Elaal GA, et al. Correlation between CAT score, inflammatory markers and pulmonary function tests in patient with acute exacerbation of COPD[J]. Egyptian J Chest Dis Tuberc,2017,66(2):243-246.
[9]	于春歌, 华毛. AECOPD患者炎症表型及炎性标志物研究进展[J]. 临床肺科杂志,2018(1):1887-1890.
[10]	Halldorsdottir HD, Eriksson J, Persson BP, et al. Heparin-binding protein as a biomarker of post-injury sepsis in trauma patients[J]. Acta Anaesth Scand,2018,35(14):201-204.
[11]	Fisher J, Adam L, Peter B, et al. Is heparin-binding protein inhibition a mechanism of albumin’s efficacy in human septic shock?[J]. Criti Care Med,2018,46(5):1-4.
[12]	罗麟洁, 唐凤鸣, 万宁, 等. 慢性阻塞性肺疾病患者诱导痰正五聚蛋白3水平的相关性研究[J]. 浙江临床医学,2017,19(8):1392-1393.
[13]	Cappuzzello C, Doni A, Dander E, et al. Mesenchymal stromal cell derived PTX3 promotes wound healing via fibrin remodeling[J]. J Investigative Dermatology,2016,136:293-295.
[14]	Ahlberg V, Hjertner B, Wallgren P, et al. Innate immune responses induced by the saponin adjuvant Matrix-M in specific pathogen free pigs[J]. Vet Res,2017,48(1):30-34.
[15]	徐雯. 肝素结合蛋白在慢性阻塞性肺疾病患者血清中的表达水平及意义[J]. 河北医药,2018,40(4):591-593.
[16]	王国双, 关博, 宋志军, 等. 血清hs-CRP, PCT, PTX3在AECOPD患者中的表达水平及临床意义[J]. 中国煤炭工业医学杂志,2019,22(1):55-59.
[17]	李昶, 金晶, 王艳春, 等. 入院后早期检测PTX3水平对老年AECOPD患者近期预后的临床研究[J]. 河北医药,2018,23(1):2453-2456.
[18]	Thulborn SJ, Dilpazir M, Haldar K, et al. Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD[J]. Int J Chron Obstruct Pulmon Dis,2017,31(12):1199-1205.
[19]	Yang F, Xiong J, Liu X, et al. SUMOylation of PTX3 at lysine 203 regulates its subcellular localization in mouse ovarian granulosa cells[J]. Pak Vet J,2017,25(37): 25-30.
[20]	Gao D, Chen X, Wu H, et al. The levels of serum pro-calcitonin and high-sensitivity C-reactive protein in the early diagnosis of chronic obstructive pulmonary disease during acute exacerbation[J]. Exp Ther Med,2017,14(1):193-198.
[21]	Chen YR, Chen V, Hollander Z, et al. C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations[J]. PLoS One,2017,12(3):e0174063.

临床指标		COPD组（60例）	COPD合并肺炎组（45例）	对照组（35例）	统计量	P值
男/女（例）		38/22	33/12	24/11	χ² = 1.336	0.273
平均年龄（ ± s，岁）		61.32 ± 9.4	59.97 ± 10.9	58.38 ± 97.1	F = 2.014	0.196
吸烟史[例（%）]		49（81.7）	35（77.8）	9（25.7）	χ² = 5.362	0.002
并发症[例（%）]		?	?	?	?	?
?	糖尿病	12（20.0）	8（17.8）	0（0.0）	χ² = 3.114	0.023
?	高血压	9（15.0）	6（13.3）	0（0.0）	χ² = 4.021	0.015
FEV1/FVC（%）（ ± s，%）		68.5 ± 10.3	55.12 ± 8.1	92.28 ± 12.3	F = 6.773	0.001
FVC（ ± s，%）		2.4 ± 0.3	1.74 ± 0.3	4.2 ± 0.51	F = 3.812	0.029
CRP（ ± s，mg/L）		45.1 ± 1.67	68.9 ± 3.5	8.9 ± 0.9	F = 5.114	0.011
PCT（ ± s，μg/L）		18.34 ± 6.7	28.98 ± 5.9	0.34 ± 0.01	F = 6.344	0.003
IL-8（ ± s，pg/ml）		890.89 ± 12.76	987.45 ± 15.6	509.5 ± 12.4	F = 5.031	0.012
TNF-α（ ± s，pg/ml）		326.7 ± 10.2	369.57 ± 14.4	167.5 ± 17.1	F = 5.208	0.014

临床指标		COPD组（60例）	COPD合并肺炎组（45例）	对照组（35例）	统计量	P值
男/女（例）		38/22	33/12	24/11	χ² = 1.336	0.273
平均年龄（ ± s，岁）		61.32 ± 9.4	59.97 ± 10.9	58.38 ± 97.1	F = 2.014	0.196
吸烟史[例（%）]		49（81.7）	35（77.8）	9（25.7）	χ² = 5.362	0.002
并发症[例（%）]		?	?	?	?	?
?	糖尿病	12（20.0）	8（17.8）	0（0.0）	χ² = 3.114	0.023
?	高血压	9（15.0）	6（13.3）	0（0.0）	χ² = 4.021	0.015
FEV1/FVC（%）（ ± s，%）		68.5 ± 10.3	55.12 ± 8.1	92.28 ± 12.3	F = 6.773	0.001
FVC（ ± s，%）		2.4 ± 0.3	1.74 ± 0.3	4.2 ± 0.51	F = 3.812	0.029
CRP（ ± s，mg/L）		45.1 ± 1.67	68.9 ± 3.5	8.9 ± 0.9	F = 5.114	0.011
PCT（ ± s，μg/L）		18.34 ± 6.7	28.98 ± 5.9	0.34 ± 0.01	F = 6.344	0.003
IL-8（ ± s，pg/ml）		890.89 ± 12.76	987.45 ± 15.6	509.5 ± 12.4	F = 5.031	0.012
TNF-α（ ± s，pg/ml）		326.7 ± 10.2	369.57 ± 14.4	167.5 ± 17.1	F = 5.208	0.014

组别	例数	HBP（pg/ml）	PTX3（ng/L）
COPD组	60	372.0 ± 22.0	5.9 ± 0.3
COPD合并肺炎组	45	558.3 ± 19.4	7.9 ± 0.5
对照组	35	295.2 ± 18.4	5.1 ± 0.9
F值	?	7.36	11.75
P值	?	0.003	0.012

组别	例数	HBP（pg/ml）	PTX3（ng/L）
COPD组	60	372.0 ± 22.0	5.9 ± 0.3
COPD合并肺炎组	45	558.3 ± 19.4	7.9 ± 0.5
对照组	35	295.2 ± 18.4	5.1 ± 0.9
F值	?	7.36	11.75
P值	?	0.003	0.012

指标	HBP		PTX3
指标	r值	P值	r值	P值
FEV1	－0.27	0.036	－0.54	0.008
FEV1/FVC（%）	－0.65	0.027	－0.28	0.015
CRP	0.23	0.039	0.46	0.028
PCT	0.12	0.031	0.37	0.032
IL-8	0.67	0.042	0.54	0.013
TNF-α	0.56	0.033	0.39	0.036

Please choose a citation manager

Content to export